Reason for request
Re-assessment of the actual benefit of third-generation oral contraceptives in response to a request by the Directorate-General for Health dated 27 December 2011.
Clinical Benefit
| Insufficient |
taking into account both the increased risk of venous thromboembolic events and the lack of demonstrated benefit in terms of clinical safety in women exposed to third-generation oral contraceptives compared with second- or first-generation oral contraceptives, the actual benefit of these proprietarymedicinal products must be regarded as insufficient for reimbursement by National Health Insurance.
|
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
SM90zTE1c5pmqMyb